STALICLA is a Swiss clinical stage biotech company on a unique mission to identify, develop and bring precision medicine to patients with neurodevelopmental disorders, with a first application in autism spectrum disorder.
STALICL A has assembled a world -class team of experienced drug developers, clinicians and computational systems biologists.
DEPI, the company's first in class NDD precision medicine platform characterizes biologically similar subgroup s of patients within highly variable populations of patients with neurodevelopmental disorders, and further identifies tailored treatments.
To support its drug discovery platform and pipeline development, STALICLA has established strong networks within top tier research and clinical centers in Europe and the United States.
STALICL A’s platform has already proven successful in accelerating and lowering risk for its first precision medicine pipeline, STP1, tailored to a subgroup of patients with autism spectrum disorder. STALICLA’s STP1 pipeline is currently in clinical trials in the US.
STALICL A is also advancing two additional in house programs and collaborative alliances with strategics around pipeline rescue programs.
STALICL A has assembled a world -class team of experienced drug developers, clinicians and computational systems biologists.
DEPI, the company's first in class NDD precision medicine platform characterizes biologically similar subgroup s of patients within highly variable populations of patients with neurodevelopmental disorders, and further identifies tailored treatments.
To support its drug discovery platform and pipeline development, STALICLA has established strong networks within top tier research and clinical centers in Europe and the United States.
STALICL A’s platform has already proven successful in accelerating and lowering risk for its first precision medicine pipeline, STP1, tailored to a subgroup of patients with autism spectrum disorder. STALICLA’s STP1 pipeline is currently in clinical trials in the US.
STALICL A is also advancing two additional in house programs and collaborative alliances with strategics around pipeline rescue programs.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Switzerland
Year Founded:
2017
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
STP1
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
